# iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

> **NCT05740280** · PHASE1 · TERMINATED · sponsor: **Cellivery Therapeutics, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** iCP-NI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05740280
- **Lead sponsor:** Cellivery Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-19
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-04-20
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Closed by Sponsor for business reasons
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740280, "iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05740280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*